ARCELLX-ACLX-001-DDBCMA
Phase I
OPEN TO ACCRUAL
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-Term Safety Follow-Up
CARGO-CRG-022-101-LBCL
Phase II
OPEN TO ACCRUAL
An Open-Label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-Cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-Cell Therapy
CARIBOU-AMPLIFY-CB12A-AML
Phase I
OPEN TO ACCRUAL
A Phase 1, Multicenter, Open-Label Study of CB-012, a CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AMpLify)
CARIBOU-CAMMOUFLAGE-CB-011A-MM
Phase I
OPEN TO ACCRUAL
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Mulitple Myeloma (CaMMouflage Trial)
CELGENE-GC-LTFU-001
Phase II/III
OPEN TO ACCRUAL
Long-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T Cells
GRACELL-GC012F-CD19-BCMA-001
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma
GSK-3377794-LTFU
Phase I
OPEN TO ACCRUAL
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
IIT-SHAH-IL7-IL15-CD20-19
Phase I/II
OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
JNJ-MY4002-CARTINUE-LTFU
Phase IV
OPEN TO ACCRUAL
Long-Term Follow-Up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
JUNO-017004-TRANSCEND-CLL
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
SOTIO-BOXR1030
Phase I/II
OPEN TO ACCRUAL *
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors